title: Protective role ofNigella sativain diabetic nephropathy: A randomized clinical trial.
abstract: This study aims to evaluate efficacy and safety of Nigella sativa oil supplementation in patients with chronic kidney disease Stage 3 and 4 due to diabetic nephropathy. It was a prospective, comparative, and open-label study. Patients were randomized into two groups. Group 1 (Control) received conservative management of diabetic nephropathy, whereas Group 2 (Test) received N. sativa oil (2.5 mL, once daily and per orally) along with conservative management for 12 weeks. Blood glucose, hemogram, and kidney function test were done at 0, 6, and 12 weeks of treatment. Significance of differences between pre- and post-treatment values in each group was assessed using Student's paired t-test and between the groups using unpaired t-test. We found a drop in blood glucose, serum creatinine, blood urea, and 24 h total urinary protein levels and a rise in glomerular filtration rate, 24 h total urinary volume, and hemoglobin level in the treatment group compared to the control group.
authors.affiliation: Department of Pharmacology, J. N. Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
authors.forename: Zafar Masood
authors.initials: ZM
authors.lastname: Ansari
authors.affiliation: Department of Pharmacology, J. N. Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Nasiruddin
authors.affiliation: Department of Pharmacology, J. N. Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
authors.forename: Rahat Ali
authors.initials: RA
authors.lastname: Khan
authors.affiliation: Department of Medicine, J. N. Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
authors.forename: Shahzad Faizul
authors.initials: SF
authors.lastname: Haque
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D003928:Diabetic Nephropathies / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D007194:India; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D031881:Nigella sativa / Q000737:chemistry; D010938:Plant Oils / Q000009:adverse effects / Q000302:isolation & purification / Q000627:therapeutic use*; D011446:Prospective Studies; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult; D029974:Carum
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D010938:Plant Oils; D003404:Creatinine; C104525:caraway oil